Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2025.0332 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Changze Hong und 29 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Cytomegalovirus, Cytomegalovirus Infections, Liver Cirrhosis, Virus Activation. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, National Natural Science Foundation Youth Fund.
Abstract (Originalsprache)
Background/Aims: The role of reactivation of human cytomegalovirus (HCMV) in determining outcomes of cirrhotic patients with acute decompensation (AD) is unknown. We aimed to investigate HCMV incidence and potential correlation with hepatic outcomes in AD patients.
Methods
Two prospective multicentre cohorts with AD patients were investigated. Patients in cohort 1 were recruited from 4 centres, while patients in cohort 2 were randomly selected from a second multicentre cohort. HCMV reactivation was established with quantitative real-time polymerase chain reaction assay in seropositive patients.
Results
HCMV reactivation was found in 35 patients from cohort 1 (n=722) and 14 from cohort 2 (n=291), with an incidence of 4.8% in both cohorts. Bacterial infection and liver failure were independently correlated with HCMV reactivation. HCMV reactivation was an independent predictor of 90-day mortality. Among bacterial infection populations in these two cohorts, patients with HCMV reactivation had worse prognosis compared to those without. Incidence of acute-on-chronic liver failure (ACLF) was higher in patients with HCMV reactivation compared to those without and was also independently correlated with development of ACLF. In a total of 49 HCMV reactivation cases, 8 patients were treated with ganciclovir, in whom a significantly lower 90-day mortality compared with those not treated was observed. All 3 patients who underwent liver transplantation with reactivation of HCMV died.
Conclusions
In AD patients, HCMV reactivation was common, especially in those with bacterial infection or liver failure, and they were more prone to having ACLF and 90‑day mortality. The data propose the need for active surveillance for HCMV infection in AD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Hepatology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Traditional and Western Medical Hepatology, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
- Centre of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
- Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- National Natural Science Foundation Youth Fund
- National Science and Technology Major Project
- Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
- Clinical Research Program of Nanfang Hospital, Southern Medical University
- Clinical Research Startup Program of Southern Medical University by High-level University Construction Funding of Guangdong Provincial Department of Education
- Key-Area Research and Development Program of Guangdong Province
Zitieren
APA
Hong, C., Huang, Z., He, Y., Wang, R., Lin, J., Liu, Y., Liu, B., Lan, X., He, Q., Luo, W., Lai, Q., Zhou, L., Qi, T., Ji, Y., Liu, M., Wu, Q., Yao, Y., Liang, W., Wang, X., …, & Chen, J. (2025). Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.0332
Vancouver
Hong C, Huang Z, He Y, Wang R, Lin J, Liu Y, et al. Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2025.0332
BibTeX
@article{Hong2025,
author = {Hong, Changze and Huang, Zuxiong and He, Yingli and Wang, Rongqi and Lin, Jiaying and Liu, Yushan and Liu, Baicheng and Lan, Xiaoqin and He, Qinjun and Luo, Wenfan and Lai, Qintao and Zhou, Ling and Qi, Tingting and Ji, Yali and Liu, Miaoxia and Wu, Qiaoping and Yao, Yichen and Liang, Weihao and Wang, Xianbo and Deng, Guohong and Gao, Yanhang and Huang, Yan and Liu, Feng and Lu, Xiaobo and Meng, Zhongji and Nan, Yuemin and Li, Hai and Li, Beiling and Jalan, Rajiv and Chen, Jinjun},
title = {Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2025.0332}
}
EUVIMED